Sight Sciences just delivered a split verdict — Q1 sales beat but earnings missed, and then management raised the full-year bar anyway. That combination is the heart of this week's setup heading into the post-earnings session.
The revenue print was the good part. Q1 sales came in at $19.7 million, above the $18.5 million consensus. Management followed up immediately with a guidance raise: full-year 2026 revenue guidance lifted to $83–$89 million, up from the prior $82–$88 million range. On the bottom line, however, the EPS loss of $0.24 ran well wide of the $0.18 estimate — a reminder that cash consumption remains a feature of this business, not a footnote. The stock entered the print at $4.33, up 23% over the prior month but still sitting well below the Street's mean price target.
Analyst sentiment is cautiously constructive, but the gap between price and target tells a nuanced story. The mean target of $8.34 implies roughly 90% upside from the current level. Most of the target-raising activity happened in late 2025, when UBS, Citigroup, Stifel, Lake Street, and Morgan Stanley all pushed numbers higher. The more recent 2026 moves have been trimming ones — UBS lowered to $11 and Citi cut to $6.50 following the March earnings print, both maintaining their ratings. Piper Sandler had been the boldest near-term mover, upgrading to Overweight in January with a $9 target. The bull case rests on MIGS market share gains and faster TearCare adoption. The bear case is familiar: persistent cash burn, delayed insurance coverage for TearCare, and growing competition in the MIGS market. The most recent analyst data is about four weeks old; how the Street digests the Q1 revenue beat against the wider EPS miss will be the next read on directional conviction.
Short positioning tells a low-key story. Short interest is running at roughly 2.1% of free float — low enough that it carries little structural weight either way. The short score of 35.7 is in the unremarkable middle of the range, essentially flat across the past two weeks. Borrow has loosened considerably; cost to borrow is at 1.5%, down about 25% on the week and roughly half the levels seen in late March when it briefly touched 3.9%. Availability is ample, meaning there is no squeeze pressure and no meaningful short-side crowding here. The borrow market is quiet.
What is worth watching on the ownership side is founder activity. Both Paul Badawi (CEO) and David Badawi (CTO) sold shares in early April at prices around $3.48–$3.70. The CFO and Chief Legal Officer also sold in the same window. These were small-dollar transactions with low significance scores — likely routine plan sales rather than a directional signal — but they occurred while the stock was near recent lows, which makes the subsequent 23% one-month rally the more striking data point. Paul Badawi remains the largest individual holder at just over 10% of shares. BlackRock added roughly 151,000 shares in Q1, and Vanguard added around 42,000, providing some passive support at the margin.
The prior two earnings events show the asymmetry that tends to follow this name. The March 2026 print (Q4 results) saw the stock fall 24.7% on the day and extend that to a nearly 30% five-day loss. The December 2025 print saw a modest 3.3% gain on day one but a 7.3% reversal by day five. Both outcomes leaned negative beyond the initial session. That record, set against a stock already up strongly into this print, is the key context for reading the post-earnings reaction this time around.
The combination of a revenue beat and guidance raise is clearly the more constructive setup compared to the March print. Whether the wider EPS miss offsets that improvement — and whether analysts revise targets higher or treat the cash burn as still the defining issue — will determine how the stock trades through the rest of the week.
See the live data behind this article on ORTEX.
Open SGHT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
